Gasdermin D Protein

Gasdermin D Protein

title: Gasdermin D Protein
description: Gasdermin D, pyroptosis executor protein, forms membrane pores, inflammasome effector
<div class="infobox infobox-protein">
<table>
<tr><th colspan="2">Gasdermin D Protein</th></tr>
<tr><td><strong>Symbol</strong></td><td>GSDMD</td></tr>
<tr><td><strong>Full Name</strong></td><td>Gasdermin D</td></tr>
<tr><td><strong>Gene</strong></td><td>[GSDMD](/genes/gsdmd)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P57764](https://www.uniprot.org/uniprotkb/P57764)</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>52.8 kDa</td></tr>
<tr><td><strong>Length</strong></td><td>487 amino acids</td></tr>
<tr><td><strong>Subcellular Location</strong></td><td>Cytoplasm, plasma membrane (upon activation)</td></tr>
<tr><td><strong>PDB Structures</strong></td><td>[6N9O](https://www.rcsb.org/structure/6N9O), [6VPE](https://www.rcsb.org/structure/6VPE)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), Sepsis, Inflammatory diseases</td></tr>
</table>
</div>

Pathway Diagram

...

Gasdermin D Protein

title: Gasdermin D Protein
description: Gasdermin D, pyroptosis executor protein, forms membrane pores, inflammasome effector
<div class="infobox infobox-protein">
<table>
<tr><th colspan="2">Gasdermin D Protein</th></tr>
<tr><td><strong>Symbol</strong></td><td>GSDMD</td></tr>
<tr><td><strong>Full Name</strong></td><td>Gasdermin D</td></tr>
<tr><td><strong>Gene</strong></td><td>[GSDMD](/genes/gsdmd)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P57764](https://www.uniprot.org/uniprotkb/P57764)</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>52.8 kDa</td></tr>
<tr><td><strong>Length</strong></td><td>487 amino acids</td></tr>
<tr><td><strong>Subcellular Location</strong></td><td>Cytoplasm, plasma membrane (upon activation)</td></tr>
<tr><td><strong>PDB Structures</strong></td><td>[6N9O](https://www.rcsb.org/structure/6N9O), [6VPE](https://www.rcsb.org/structure/6VPE)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), Sepsis, Inflammatory diseases</td></tr>
</table>
</div>

Pathway Diagram

Overview

Gasdermin D is a protein encoded by the [GSDMD](/genes/gsdmd) gene that serves as the central executor of pyroptotic cell death. This page describes its structure, normal nervous system function, role in neurodegenerative disease, and potential as a therapeutic target.

Structure

Gasdermin D is the central executor of pyroptosis, a pro-inflammatory form of programmed cell death:

Domain Architecture

• N-terminal domain (NTD) (residues 1-242): Pore-forming domain, cytotoxic when cleaved
• Linker region (residues 243-275): Flexible segment containing cleavage sites
• C-terminal domain (CTD) (residues 276-487): Autoinhibitory domain that masks NTD

Autoinhibition

• In full-length GSDMD, CTD binds and masks the NTD
• This intramolecular interaction prevents pore formation
• Cleavage by inflammatory caspases releases the NTD from inhibition

Pore Structure

• NTD monomers oligomerize to form large transmembrane pores
• Each pore contains 16-24 subunits
• Pore diameter: 10-14 nm, sufficient for IL-1β and IL-18 release
• Forms arc-shaped or slit-shaped oligomers on membranes

Normal Function

Pyroptosis Execution

GSDMD is the essential executor of inflammatory cell death:

Dormant state: Full-length GSDMD is autoinhibited in the cytoplasm

Caspase activation: Inflammatory caspases (caspase-1, -4, -5, -11) cleave GSDMD

NTD release: Cleavage separates NTD from autoinhibitory CTD

Membrane translocation: NTD translocates to plasma membrane

Pore formation: NTD oligomerizes into large transmembrane pores

Cell lysis: Pores cause osmotic swelling and membrane rupture

Inflammasome Pathway

• Canonical pathway: Caspase-1 (activated by inflammasomes) cleaves GSDMD
• Non-canonical pathway: Caspase-4/5 (human) or caspase-11 (mouse) cleave GSDMD
• Cleavage site: After Asp-275 (FLTD|G sequence)

IL-1β/IL-18 Release

• GSDMD pores allow passive release of mature cytokines
• Also creates channels for gasdermin-mediated cytokine secretion
• Critical for inflammatory signaling in infection and sterile inflammation

Role in Neurodegeneration

Alzheimer's Disease

GSDMD-mediated pyroptosis contributes to AD pathology:

[NLRP3 inflammasome](/entities/nlrp3-inflammasome) activation: [Aβ](/proteins/amyloid-beta) aggregates trigger NLRP3 activation

GSDMD cleavage: Active caspase-1 cleaves GSDMD in [microglia](/cell-types/microglia-neuroinflammation)

Pyroptotic microglia death: GSDMD pores cause microglial lysis

IL-1β release: GSDMD pores facilitate IL-1β/IL-18 release, amplifying inflammation

Neuronal damage: IL-1β and other inflammatory mediators damage [neurons](/entities/neurons)

Parkinson's Disease

• [α-synuclein](/proteins/alpha-synuclein)-induced pyroptosis: Fibrillar α-synuclein activates inflammasome
• Microglial pyroptosis: GSDMD activation in microglia contributes to neuroinflammation
• Dopaminergic neuron death: Inflammatory milieu from pyroptosis damages neurons

Multiple Sclerosis

• Demyelination-associated pyroptosis: GSDMD activation in immune cells
• [Blood-brain barrier](/entities/blood-brain-barrier) disruption: GSDMD pores may contribute to BBB breakdown
• Therapeutic target: GSDMD inhibition shows promise in EAE models

Stroke and Traumatic Brain Injury

• Acute neuroinflammation: Rapid GSDMD activation following injury
• Neuronal pyroptosis: Direct GSDMD activation in neurons under severe stress
• Secondary damage: Pyroptosis amplifies inflammatory cascade

Molecular Mechanisms

Cleavage by Inflammatory Caspases

| Caspase | Species | Context | Cleavage Site |
|---------|---------|---------|---------------|
| Caspase-1 | Human/Mouse | Canonical inflammasome | D275 |
| Caspase-4 | Human | LPS sensing | D275 |
| Caspase-5 | Human | Non-canonical | D275 |
| Caspase-11 | Mouse | Non-canonical | D276 |

Pore Formation Process

Lipid binding: NTD binds phosphoinositides (PI(4,5)P2) and cardiolipin

Membrane insertion: α-helices insert into lipid bilayer

Oligomerization: 16-24 NTD subunits assemble into pore

Membrane rupture: Pores destabilize membrane integrity

Downstream Effects

• Osmotic lysis: Uncontrolled ion/water flux causes cell swelling
• DNA damage: Nuclear envelope pores allow DNA-damaging factors
• Content release: Cytosolic contents including DAMPs are released

Therapeutic Targeting

Small Molecule Inhibitors

• Necrosulfonamide (NSA): Covalently modifies GSDMD C191, blocks pore formation
• Disulfiram: Repurposed drug inhibits GSDMD pore formation
• DMF (dimethyl fumarate): Modifies GSDMD C191, reduces pyroptosis

Genetic Approaches

• GSDMD knockout mice: Protected from inflammasome-mediated pathology
• CRISPR targeting: GSDMD gene editing for inflammatory diseases

Clinical Applications

• Sepsis: GSDMD inhibition reduces systemic inflammation
• Neuroinflammation: Potential for treating AD, PD, MS
• Autoinflammatory diseases: GSDMD targeting in CAPS and related disorders

Key Interactions

| Interacting Protein | Function | Disease Relevance |
|-------------------|----------|-------------------|
| Caspase-1 | Canonical inflammasome effector | AD, PD, MS |
| Caspase-4/5 | Non-canonical activation | Sepsis |
| NLRP3 | Inflammasome sensor | AD, gout |
| ASC/PYCARD | Inflammasome adaptor | AD, PD |
| IL-1β | Cytokine release through pores | Neuroinflammation |

See Also

• [GSDMD Gene](/genes/gsdmd)
• [NLRP3 Inflammasome](/mechanisms/nlrp3-inflammasome)
• [Pyroptosis](/mechanisms/pyroptosis)
• [Neuroinflammation](/mechanisms/neuroinflammation)
• [Caspase-1](/proteins/casp1)

External Links

• [UniProt: P57764](https://www.uniprot.org/uniprotkb/P57764)
• [NCBI Gene: 79792](https://www.ncbi.nlm.nih.gov/gene/79792)
• [PDB: 6N9O](https://www.rcsb.org/structure/6N9O)

References

[Shi et al., GSDMD mediates caspase-dependent pyroptosis (2015) (2015)](https://doi.org/10.1038/nature15514)

[Kayagaki et al., Caspase-11 cleaves GSDMD for non-canonical pyroptosis (2015) (2015)](https://doi.org/10.1038/nature15516)

[Ding et al., Pore-forming activity and structural autoinhibition of GSDMD (2016) (2016)](https://doi.org/10.1038/nature18590)

[Liu et al., GSDMD-mediated pyroptosis in neurodegeneration (2020) (2020)](https://doi.org/10.1038/s41583-020-0306-4)

[Ising et al., NLRP3 inflammasome and GSDMD in AD (2019) (2019)](https://doi.org/10.1038/s41586-019-1179-2)

[Rathkey et al., GSDMD inhibitor necrosulfonamide (2018) (2018)](https://doi.org/10.1038/s41590-018-0033-3)

[Hu et al., GSDMD structural mechanisms (2020) (2020)](https://doi.org/10.1038/s41586-020-2946-5)

[Xia et al., Pyroptosis in neurodegenerative diseases (2021) (2021)](https://doi.org/10.1016/j.neuron.2021.05.031)

[Wang et al., GSDMD as therapeutic target (2021) (2021)](https://doi.org/10.1038/s41573-021-00266-6)

[Zhang et al., Disulfiram inhibits GSDMD pore formation (2020) (2020)](https://doi.org/10.1126/sciimmunol.aav8629)

Pathway Diagram

The following diagram shows the key molecular relationships involving Gasdermin D Protein discovered through SciDEX knowledge graph analysis: